Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222891 · ClinicalTrials.gov registry record · Phase 2
Impact of Smell Testing on Health Outcomes
A Phase 2 study, sponsored by Monell Chemical Senses Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
NCT07222891: Clinical Trial Phase 2 study, sponsored by Monell Chemical Senses Center.
NCT07222891 is a Phase 2 study that has not yet begun recruiting, run by Monell Chemical Senses Center. The registered enrollment target is 1,000 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (652% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222891, a Phase 2 study, has not yet begun recruiting, sponsored by Monell Chemical Senses Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.
Primary Outcome
The PHQ-9 is a screening measure of depressive symptoms.
Interventions
- BEHAVIORAL Patient-centered information and education
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
What is known before NCT07222891 opens enrollment
NCT07222891 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (652% higher).
The record links to 0 conditions, and to 1 intervention - of which Patient-centered information and education is the first listed.
NCT07222891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07222891 about?
NCT07222891 is a clinical study titled "Impact of Smell Testing on Health Outcomes". Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to ...
What is the current status of trial NCT07222891?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2025-11-01. Estimated completion is 2027-11-30.
What interventions are being tested in trial NCT07222891?
The interventions under investigation include: Patient-centered information and education (BEHAVIORAL).
Who is sponsoring clinical trial NCT07222891?
This trial is sponsored by Monell Chemical Senses Center, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07222891's enrollment target sits among peer trials
1,000 25th of 2000 higher than 1,975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI